The FDA approved Johnson & Johnson and Medivir's Olysio, or simeprevir, in combination with interferon and ribavirin, as a treatment for chronic hepatitis C infection. Data from clinical trials showed that the virus could not be detected in about 8 in 10 patients after treatment with Olysio. The drug is the third protease inhibitor to be cleared by the FDA for this indication. A decision is expected next month on a new class of hepatitis C drug from Gilead Sciences.

Full Story:
Bloomberg, Reuters

Related Summaries